Can be percutaneous nephrolithotomy (PCNL) considered as a first-line treatment in all cases of stones larger than 2 cm? The expanding role of retrograde intrarenal surgery (RIRS)

2019 ◽  
Vol 18 (7) ◽  
pp. e2776
Author(s):  
A. Artiles Medina ◽  
I. Laso García ◽  
M. Ruiz Hernández ◽  
G. Duque Ruiz ◽  
F. Arias Funez ◽  
...  
Keyword(s):  
Percutaneous Nephrolithotomy ◽  
Line Treatment ◽  
First Line ◽  
Retrograde Intrarenal Surgery ◽  
First Line Treatment

A REVIEW ON THE ROLE OF TYROSINE KINASE INHIBITORS AVAILABLE FOR THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA

2020 ◽  
Vol 7 (2) ◽  
pp. 205-211
Author(s):  
Kaynat Fatima ◽  
Syed Tasleem Raza ◽  
Ale Eba ◽  
Sanchita Srivastava ◽  
Farzana Mahdi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Protein Kinases ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

The function of protein kinases is to transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are linked to the initiation and development of human cancer. The recent development of small molecule kinase inhibitors for the treatment of different types of cancer in clinical therapy has proven successful. Significantly, after the G-protein-coupled receptors, protein kinases are the second most active category of drug targets. Imatinib mesylate was the first tyrosine kinase inhibitor (TKI), approved for chronic myeloid leukemia (CML) treatment. Imatinib induces appropriate responses in ~60% of patients; with ~20% discontinuing therapy due to sensitivity, and ~20% developing drug resistance. The introduction of newer TKIs such as, nilotinib, dasatinib, bosutinib, and ponatinib has provided patients with multiple options. Such agents are more active, have specific profiles of side effects and are more likely to reach the necessary milestones. First-line treatment decisions must be focused on CML risk, patient preferences and comorbidities. Given the excellent result, half of the patients eventually fail to seek first-line treatment (due to discomfort or resistance), with many of them needing a third or even further therapy lines. In the present review, we will address the role of tyrosine kinase inhibitors in therapy for chronic myeloid leukemia.

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

2009 ◽  
Vol 9 (4) ◽  
pp. 425-435 ◽  
Author(s):  
Marcello Tiseo ◽  
Marco Bartolotti ◽  
Francesco Gelsomino ◽  
Andrea Ardizzoni
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Histologic Subtype ◽  
First Line Treatment

scholarly journals Role of VAD Regimen as the First-Line Treatment in Multiple Myeloma

2013 ◽  
Vol 8 (2) ◽  
pp. 64-69
Author(s):  
SS Mahmood ◽  
AKM Abedin ◽  
H Islam ◽  
N Jubaida ◽  
NM Kawsar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

DOI: http://dx.doi.org/10.3329/jafmc.v8i2.16357 JAFMC Vol.8(2) 2012 pp.64-69

Role of Catheter Ablation as a First-Line Treatment for Atrial Fibrillation

2020 ◽  
Vol 22 (11) ◽  
Author(s):  
Ibrahim El Masri ◽  
Sharif M Kayali ◽  
Theodore Manolukas ◽  
Yehoshua C. Levine
Keyword(s):  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals The role of maintenance therapy in the first line treatment of metastatic colorectal cancer

2018 ◽  
Vol 29 ◽  
pp. v63
Author(s):  
D. Gridnev ◽  
A. Popov ◽  
E. Vozny ◽  
V. Makarov ◽  
D. Islamova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Maintenance Therapy ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma

2017 ◽  
Vol 1 (24) ◽  
pp. 2138-2146 ◽  
Author(s):  
Young Ae Kim ◽  
Ja Min Byun ◽  
Keeho Park ◽  
Gi Hwan Bae ◽  
Dukhyoung Lee ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Lymphoma ◽  
Line Treatment ◽  
First Line ◽  
Peripheral T Cell Lymphoma ◽  
Hematopoietic Stem ◽  
Asian Populations ◽  
Key Points ◽  
First Line Treatment

Key Points Etoposide addition/chemo-intensification has little role in first-line treatment of PTCL in Asian populations, regardless of subtype or age. Upfront hematopoietic stem-cell transplantation as consolidation seems like a legitimate choice in patients with PTCL.

Sign in / Sign up

Export Citation Format

Share Document